In the last decade, the qPCR and dPCR market witnessed significant technological advancements and robust product development. These advancements have helped to transform various qPCR and dPCR applications in nucleic acid detection & quantification, quantitative gene expression analysis, genotyping, SNP analysis, pathogen detection, and drug target validation.
North America and Europe are mature markets for qPCR and dPCR products. However, the emerging nations in Asia-Pacific (specifically China and India) are expected to become new revenue-generating pockets for qPCR and dPCR manufacturers in the next five years. The North American qPCR and dPCR products market is expected to hold the largest share during the forecast period owing to high penetration of qPCR and dPCR technologies among key end users and increasing public and private funding for the development of qPCR and dPCR technologies.
The Asia-Pacific region is expected to witness the highest market growth for qPCR and dPCR products during the forecast period. Market growth for qPCR and dPCR products in APAC is mainly fueled by awareness related to gene-based disease diagnosis and treatment, growing public and private support to develop novel qPCR and dPCR technologies, the rise of the Indian genomics market, and strengthening cancer research in Japan. Due to the significant growth opportunities offered by emerging countries, a number of players operating in the market are focusing on expanding their product distribution networks across emerging countries.
Quantitative PCR (qPCR) is one of the most-preferred PCR technologies owing to its low procedural costs and technological benefits as compared to traditional PCR. Based on applications, the qPCR and dPCR market is segmented into clinical, research, and forensic applications. The clinical applications segment is expected to grow at the highest CAGR owing to the technological benefits offered by dPCR over qPCR and traditional PCR, growing adoption of dPCR among hospitals and diagnostic centers, increasing global burden of cancer and AIDS, and expansion in distribution networks of emerging dPCR product manufacturers. Furthermore, forensic applications are expected to drive future growth of qPCR and dPCR products in the next decade owing to expansion of forensic laboratories and expected adoption of qPCR/dPCR analysis procedure in forensics (followed by significant decrease in qPCR/dPCR procedural costs with time)
As of 2015, the leading players in the qPCR and dPCR market include Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (The Netherlands), and Agilent Technologies, Inc. (U.S.), BioMerieux S.A. (France), Fluidigm Corporation (U.S.), Takara Bio Inc. (Japan), Affymetrix Inc. (U.S.), and RainDance Technologies, Inc. (U.S.).